DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01021527

CompletedPhase 1

A Study to Assess the Effects of Exenatide on Insulin Secretion Rates Using a Graded Infusion of Intravenous Glucose (0000-099)(COMPLETED)

A Randomized, 4-Period Study to Assess the Effects of Exenatide on Insulin Secretion Rates Using a Graded Infusion of Intravenous Glucose

Asset

Exenatide

GLP-1 agonist

Listed sites

0

Recruiting sites

—

Enrollment

12

actual

Study population

Healthy volunteers

Key I/E criterion

•Male

Primary endpoint

•Beta-cell glucose sensitivity

Identifiers

Registered as

NCT IDNCT01021527
Org study ID0000-099
Secondary ID099
Secondary ID2009_697

Timeline

Milestones

Study first posted2009-11-30estimated
Last update posted2015-04-28estimated
Study start2008-02 (month precision)
Primary completion2008-03actual (month precision)
Study completion2008-04actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age18 Years
Maximum age45 Years
SexMale
Healthy volunteersAccepted

Inclusion criteria

•Subject is in good health
•Subject is a non-smoker

Exclusion criteria

•Subject has irritable bowel disease
•Subject has a history of cancer
•Subject has a history of hypertension requiring treatment
•Subject is unable to refrain from the use of any prescription or non-prescription medication
•Subject consumes excessive amounts of alcohol or caffeine
•Subject has had major surgery, donated blood or participated in another investigational study in the past 4 weeks

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
1
Safety / tolerability / PK
1

Glycemic / diabetes

1 endpoint
Primary/protocol endpoint

beta-cell glucose sensitivity (slope of the relationship between insulin secretion rate and glucose)

Time frame:0-160 minutes after start of infusion

descriptive

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

safety and tolerability of a graded glucose infusion procedure measured by the number of clinical adverse experiences

Time frame:11 weeks

Treatment-emergent AEs (any)

event count, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.